This site is intended for Healthcare professionals only.

FIND joins hands with CIPLA, UNITAID to overcome HCV infection in the country


FIND joins hands with CIPLA, UNITAID to overcome HCV infection in the country

 

New Delhi: FIND, a global non-profit organization, has joined hands with Cipla to improve the availability of diagnostic and treatment systems for Hepatitis C in the interiors of  India. According to data available approximately 12 million Indians are threatened by this viral  blood  infection,that often leads to liver diseases like Cirrhosis or Cancer and ultimately death.

The focal points of the FIND, Cipla partnership include improvement of Hepaptitis C virus diagnosis, sensitivity and scaling up of  viral infection treatments.

UNITAID, a global health initiative working under the umbrella of UN’s World Health Organization (WHO), is planning to  sign a grant agreement with FIND. Its objective being to provide both diagnostic access and treatment for Hepatitis in eight countries, including India.The sum of  grant, which is being negotiated with FIND,  would be worth several million dollars, according to Lelio Marmora, Executive Director of UNITAID

A FIND statement on the UNITAID project stated that it would work towards obtaining regulatory approvals for the new, simplified and high-quality HCV diagnostic tests, tie ups for  preferential pricing agreements with test suppliers, and incorporation of new HCV tests in existing HIV programmes. This, the statement added would be done with  the objective to begin scaling up access to HCV diagnosis and treatment, among the most vulnerable populations.

It has been found that more and more patients infected with HIV are  coming down with Hepatitis C infections . Talking to  Business Line, Lelio Marmora, highlighted  that of those infected with HIV  many were  dying due to Hepatitis C, instead of the former. ‘This makes it imperative to make Hepatitis C treatment more accessible,’ he added.

Cipla’s  generic tablets for the treatment of Hepatitis C  was launched in 2015 and costed a fraction of the price of existing medicines. The Cipla drug, Hepcvir-L, which is the generic version of Gilead Science Inc’s Harvoni tablets, is priced at Rs. 25,000 a bottle, containing 28 tablets. A twelve week course of the medication amounts to Rs, 75,000 . Gilead’s Haryoni a more expensive version is  priced at over $75,000 or $50,00,000 for the entire treatment.

In 2014 Cipla along with 5 other Indian companies had signed a licensing pact with Gilead to manufacture the drug’s generic version. Denis Broun, Head of Government Affairs at Cipla, said, “As prices (of the treatment) keep decreasing, several states have started financing the treatment of Hepatitis C, so that  it can be made available to low-income patients.”

Talking to the Hindu, Broun clarified that the prevailing diagnostic tests were neither economical nor fast, given the fact that they happen to be a   two-step process. According to FIND estimates it takes over $100 (over ₹6,500) to diagnose a single case today.

Both the companies are trying to resolve the process, price issue also.

 

 

 



Source: Inputs from the Hindu
0 comment(s) on FIND joins hands with CIPLA, UNITAID to overcome HCV infection in the country

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted